Analysts Expect 10% Gains Ahead For The Holdings of DIVB
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 22 2025
0mins
Should l Buy XRAY?
Source: NASDAQ.COM
ETF Analyst Target Price Insights: The iShares Core Dividend ETF (DIVB) has an implied analyst target price of $53.27, indicating a potential upside of 10.47% from its current trading price of $48.22. Notable underlying holdings with significant upside include DENTSPLY SIRONA Inc, Victory Capital Holdings Inc, and Cohen & Steers Inc.
Market Sentiment and Analyst Justifications: There are questions regarding whether analysts' target prices are justified or overly optimistic, as high targets may reflect future optimism but could also lead to downgrades if they do not align with recent market developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XRAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XRAY
Wall Street analysts forecast XRAY stock price to rise
16 Analyst Rating
2 Buy
13 Hold
1 Sell
Hold
Current: 12.090
Low
12.00
Averages
13.04
High
17.00
Current: 12.090
Low
12.00
Averages
13.04
High
17.00
About XRAY
DENTSPLY SIRONA Inc. is a diversified manufacturer of professional dental products and technologies. It develops, manufactures, and markets comprehensive solutions offering dental and oral health products, as well as other consumable medical devices. Its Connected Technology Solutions segment includes the design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of the Company's value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and digital orthodontic solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for both urinary and bowel management.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Close: S&P 500 Hits All-Time High
- Market Performance: On Wednesday, the S&P 500 rose by 0.80% and the Nasdaq 100 by 1.40%, reaching all-time highs, reflecting investor optimism regarding a potential peace deal in the Middle East, which may boost market confidence.
- Economic Data: The April Empire Manufacturing Survey index increased by 11.2 to 11.0, surpassing expectations and indicating improved economic activity that could support the stock market, while the NAHB housing market index fell to a 7-month low, signaling weakness in the real estate sector.
- Interest Rate Dynamics: The 10-year Treasury yield rose to 4.276% as optimism over the US-Iran ceasefire eased safe-haven demand for Treasuries, potentially leading investors to reassess future rate policies amid mixed economic signals.
- Sector Volatility: Software stocks surged, with Atlassian up over 10%, while industrial stocks fell broadly due to concerns over US metals tariffs, exemplified by Carrier Global's decline of over 9%, highlighting significant sector divergence.
See More
US Stocks Show Mixed Movement Amid Optimism Over Middle East Peace Talks
- Market Performance: The S&P 500 Index rose by 0.36%, reaching a two-month high, while the Nasdaq 100 increased by 0.63%, marking a 2.5-month high, reflecting investor optimism surrounding potential peace talks in the Middle East.
- Economic Data: The April Empire Manufacturing Survey reported a rise of 11.2 in the general business conditions index to 11.0, surpassing expectations, indicating a robust manufacturing recovery; however, the April NAHB housing market index fell to 34, signaling weakness in the housing sector that could dampen investor confidence.
- Oil Price Fluctuations: WTI crude oil prices increased by over 1% due to the U.S. naval blockade in the Strait of Hormuz, which could exacerbate global oil and fuel shortages, impacting profitability in related sectors.
- Earnings Season: Q1 earnings for the S&P 500 are projected to grow by 12% year-over-year, but excluding the technology sector, growth is only expected to be around 3%, indicating a slowdown in overall earnings growth that may affect market sentiment.
See More
US Stocks Show Modest Gains Amid Optimism Over Middle East Peace Talks
- Market Performance: The S&P 500 index rose by 0.10% and the Nasdaq 100 by 0.15%, reflecting optimism surrounding potential peace talks in the Middle East, with the S&P 500 reaching a two-month high and the Nasdaq 100 a 2.5-month high.
- Supportive Economic Data: The April Empire manufacturing survey reported a rise of 11.2 in the general business conditions index to a five-month high of 11.0, surpassing expectations of 0.0, indicating a strong economic recovery that could further boost investor confidence.
- Impact of Rising Oil Prices: WTI crude oil prices increased by over 1% as the US implemented a naval blockade in the Strait of Hormuz, potentially exacerbating global oil and fuel shortages, which could affect market supply-demand dynamics and lead to stock volatility.
- Earnings Season Insights: Q1 earnings for the S&P 500 are projected to grow by 12% year-over-year, but excluding the technology sector, growth is only expected at 3%, indicating a lack of overall earnings momentum that may affect long-term investor confidence.
See More
Dentsply Sirona Board Member Increases Stock Holdings
- Stock Purchase Transaction: Gregory T. Lucier, a board member of Dentsply Sirona, purchased 15,000 shares at an average price of $12.45 per share on March 9, 2026, totaling approximately $187,000, indicating his bullish outlook on the company's future.
- Ownership Structure Change: Following this transaction, Lucier's indirect holdings increased to 24,987,284 shares, while direct holdings remain at zero, highlighting that he holds all shares through trusts and related entities, thereby reinforcing his influence within the company.
- Historical Trading Pattern: Lucier has executed 13 trades since November 2024, with only one prior sell trade, demonstrating his consistent confidence in the company's growth prospects, especially amid the current stock price decline.
- Market Valuation Context: The average purchase price was below the March 9, 2026 closing price of $12.80, and considering the stock's 16.4% decline over the past year, it suggests Lucier views the current stock price as attractive, potentially offering a buying opportunity for investors.
See More
Analysis of High-Yield Stocks in Pharma Sector
- Pfizer's Dividend Yield: Pfizer's forward-looking dividend yield has risen to 6.5%, despite its annual revenue declining from over $60 billion in 2022, indicating investor optimism about its upcoming blockbuster drugs, which may attract income-seeking investors.
- Dentsply Sirona's Growth Potential: While Dentsply Sirona's dividend yield is slightly below 5%, its dividend payments have more than doubled over the past decade, showcasing strong dividend growth potential that long-term investors should consider.
- Bristol Myers Squibb's Stability: Bristol Myers Squibb has raised its dividend for 17 consecutive years, and despite its stock price being volatile over the past decade, its profitability remains robust, particularly due to ongoing cash flows from blockbuster drugs like Eliquis and Opdivo.
- Investor Choices: Although Pfizer did not make the Motley Fool's list of top stocks, its undervalued stock price and high dividend yield may present an attractive buying opportunity for investors seeking income in the healthcare sector.
See More
Top High-Yield Healthcare Stocks to Consider
- Pfizer's Current Status: Pfizer (PFE) has seen its annual revenue decline from over $100 billion in 2022 to below $60 billion due to reduced demand for its Comirnaty vaccine and Paxlovid treatment, resulting in its stock price dropping to less than half of its late-2021 peak, currently priced at $26.80 with a market cap of $152 billion and a dividend yield of 6.42%.
- Dentsply Sirona's Growth Potential: Dentsply Sirona (XRAY) offers a dividend yield slightly above 5%, and while it may not increase its annual payout every year, its dividend payments have more than doubled over the past decade, indicating stability and long-term growth potential in the dental supplies market, with a current stock price of $60.59.
- Bristol Myers Squibb's Profitability: Bristol Myers Squibb (BMY) has not seen net growth in its stock price over the past decade, yet it remains profitable with blockbuster drugs like Eliquis and Opdivo, providing steady cash flow, and its dividend yield stands at 4.11%, having been raised for 17 consecutive years, showcasing financial stability.
- Investment Opportunity Analysis: Despite short-term challenges faced by Pfizer and Bristol Myers Squibb, their high dividend yields and potential for new drug developments make these stocks attractive within the healthcare sector, especially during market downturns, allowing investors to capitalize on these undervalued stocks for long-term gains.
See More
US Stocks Close: S&P 500 Hits All-Time High
- Market Performance: On Wednesday, the S&P 500 rose by 0.80% and the Nasdaq 100 by 1.40%, reaching all-time highs, reflecting investor optimism regarding a potential peace deal in the Middle East, which may boost market confidence.
- Economic Data: The April Empire Manufacturing Survey index increased by 11.2 to 11.0, surpassing expectations and indicating improved economic activity that could support the stock market, while the NAHB housing market index fell to a 7-month low, signaling weakness in the real estate sector.
- Interest Rate Dynamics: The 10-year Treasury yield rose to 4.276% as optimism over the US-Iran ceasefire eased safe-haven demand for Treasuries, potentially leading investors to reassess future rate policies amid mixed economic signals.
- Sector Volatility: Software stocks surged, with Atlassian up over 10%, while industrial stocks fell broadly due to concerns over US metals tariffs, exemplified by Carrier Global's decline of over 9%, highlighting significant sector divergence.
See More
US Stocks Show Mixed Movement Amid Optimism Over Middle East Peace Talks
- Market Performance: The S&P 500 Index rose by 0.36%, reaching a two-month high, while the Nasdaq 100 increased by 0.63%, marking a 2.5-month high, reflecting investor optimism surrounding potential peace talks in the Middle East.
- Economic Data: The April Empire Manufacturing Survey reported a rise of 11.2 in the general business conditions index to 11.0, surpassing expectations, indicating a robust manufacturing recovery; however, the April NAHB housing market index fell to 34, signaling weakness in the housing sector that could dampen investor confidence.
- Oil Price Fluctuations: WTI crude oil prices increased by over 1% due to the U.S. naval blockade in the Strait of Hormuz, which could exacerbate global oil and fuel shortages, impacting profitability in related sectors.
- Earnings Season: Q1 earnings for the S&P 500 are projected to grow by 12% year-over-year, but excluding the technology sector, growth is only expected to be around 3%, indicating a slowdown in overall earnings growth that may affect market sentiment.
See More
US Stocks Show Modest Gains Amid Optimism Over Middle East Peace Talks
- Market Performance: The S&P 500 index rose by 0.10% and the Nasdaq 100 by 0.15%, reflecting optimism surrounding potential peace talks in the Middle East, with the S&P 500 reaching a two-month high and the Nasdaq 100 a 2.5-month high.
- Supportive Economic Data: The April Empire manufacturing survey reported a rise of 11.2 in the general business conditions index to a five-month high of 11.0, surpassing expectations of 0.0, indicating a strong economic recovery that could further boost investor confidence.
- Impact of Rising Oil Prices: WTI crude oil prices increased by over 1% as the US implemented a naval blockade in the Strait of Hormuz, potentially exacerbating global oil and fuel shortages, which could affect market supply-demand dynamics and lead to stock volatility.
- Earnings Season Insights: Q1 earnings for the S&P 500 are projected to grow by 12% year-over-year, but excluding the technology sector, growth is only expected at 3%, indicating a lack of overall earnings momentum that may affect long-term investor confidence.
See More
Dentsply Sirona Board Member Increases Stock Holdings
- Stock Purchase Transaction: Gregory T. Lucier, a board member of Dentsply Sirona, purchased 15,000 shares at an average price of $12.45 per share on March 9, 2026, totaling approximately $187,000, indicating his bullish outlook on the company's future.
- Ownership Structure Change: Following this transaction, Lucier's indirect holdings increased to 24,987,284 shares, while direct holdings remain at zero, highlighting that he holds all shares through trusts and related entities, thereby reinforcing his influence within the company.
- Historical Trading Pattern: Lucier has executed 13 trades since November 2024, with only one prior sell trade, demonstrating his consistent confidence in the company's growth prospects, especially amid the current stock price decline.
- Market Valuation Context: The average purchase price was below the March 9, 2026 closing price of $12.80, and considering the stock's 16.4% decline over the past year, it suggests Lucier views the current stock price as attractive, potentially offering a buying opportunity for investors.
See More
Analysis of High-Yield Stocks in Pharma Sector
- Pfizer's Dividend Yield: Pfizer's forward-looking dividend yield has risen to 6.5%, despite its annual revenue declining from over $60 billion in 2022, indicating investor optimism about its upcoming blockbuster drugs, which may attract income-seeking investors.
- Dentsply Sirona's Growth Potential: While Dentsply Sirona's dividend yield is slightly below 5%, its dividend payments have more than doubled over the past decade, showcasing strong dividend growth potential that long-term investors should consider.
- Bristol Myers Squibb's Stability: Bristol Myers Squibb has raised its dividend for 17 consecutive years, and despite its stock price being volatile over the past decade, its profitability remains robust, particularly due to ongoing cash flows from blockbuster drugs like Eliquis and Opdivo.
- Investor Choices: Although Pfizer did not make the Motley Fool's list of top stocks, its undervalued stock price and high dividend yield may present an attractive buying opportunity for investors seeking income in the healthcare sector.
See More
Top High-Yield Healthcare Stocks to Consider
- Pfizer's Current Status: Pfizer (PFE) has seen its annual revenue decline from over $100 billion in 2022 to below $60 billion due to reduced demand for its Comirnaty vaccine and Paxlovid treatment, resulting in its stock price dropping to less than half of its late-2021 peak, currently priced at $26.80 with a market cap of $152 billion and a dividend yield of 6.42%.
- Dentsply Sirona's Growth Potential: Dentsply Sirona (XRAY) offers a dividend yield slightly above 5%, and while it may not increase its annual payout every year, its dividend payments have more than doubled over the past decade, indicating stability and long-term growth potential in the dental supplies market, with a current stock price of $60.59.
- Bristol Myers Squibb's Profitability: Bristol Myers Squibb (BMY) has not seen net growth in its stock price over the past decade, yet it remains profitable with blockbuster drugs like Eliquis and Opdivo, providing steady cash flow, and its dividend yield stands at 4.11%, having been raised for 17 consecutive years, showcasing financial stability.
- Investment Opportunity Analysis: Despite short-term challenges faced by Pfizer and Bristol Myers Squibb, their high dividend yields and potential for new drug developments make these stocks attractive within the healthcare sector, especially during market downturns, allowing investors to capitalize on these undervalued stocks for long-term gains.
See More
